{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:49:07Z","timestamp":1780087747593,"version":"3.54.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T00:00:00Z","timestamp":1415750400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s10072-014-2000-5","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T16:44:54Z","timestamp":1415983494000},"page":"599-605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48\u00a0weeks follow-up"],"prefix":"10.1007","volume":"36","author":[{"given":"Jin-Sung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Gyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Chul","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,12]]},"reference":[{"key":"2000_CR1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Ploeg van der","year":"2008","unstructured":"van der Ploeg AT, Reuser A (2008) Lysosomal storage disease 2: Pompe\u2019s disease. Lancet 372:1342\u20131353","journal-title":"Lancet"},{"issue":"7","key":"2000_CR2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-7-35","volume":"7","author":"A Herzog","year":"2012","unstructured":"Herzog A, Hartung R, Reuser AJ, Hermanns P, Runz H, Krabul N et al (2012) A cross-sectional single-centre study on the spectrum of Pompe disease, german patients: molecular analysis of the GAA gene, manifestation and gentotype\u00a0=\u00a0phenotype correlations. Orphanet J Rare Dis 7(7):35","journal-title":"Orphanet J Rare Dis"},{"key":"2000_CR3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.nmd.2009.11.006","volume":"20","author":"P Laforet","year":"2010","unstructured":"Laforet P, Doppler V, Caillaud C, Laloui K, Claeys KG, Richard P et al (2010) Rigid spine syndrome revealing late-onset Pompe disease. Neuromuscul Disord 20:128\u2013130","journal-title":"Neuromuscul Disord"},{"key":"2000_CR4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","volume":"128","author":"ML Hagemans","year":"2005","unstructured":"Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ et al (2005) Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients. Brain 128:671\u2013677","journal-title":"Brain"},{"key":"2000_CR5","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","volume":"260","author":"A Toscano","year":"2013","unstructured":"Toscano A, Schoser B (2013) Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 260:951\u2013959","journal-title":"J Neurol"},{"key":"2000_CR6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jns.2006.09.012","volume":"251","author":"YE Park","year":"2006","unstructured":"Park YE, Park KH, Lee CH, Kim CM, Kim DS (2006) Two new missense mutations of GAA in late onset glycogen storage disease type II. J Neurol Sci 251:113\u2013117","journal-title":"J Neurol Sci"},{"key":"2000_CR7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.38.10.1639","volume":"38","author":"RP Kleyweg","year":"1988","unstructured":"Kleyweg RP, van der Meche FG, Meulstee J (1988) Treatment of Guillain Barre syndrome with high-dose gammaglobulin. Neurology 38:1639\u20131641","journal-title":"Neurology"},{"key":"2000_CR8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1164\/ajrccm.167.9.950","volume":"167","author":"D Brooks","year":"2003","unstructured":"Brooks D, Solway S, Gibbons WJ (2003) ATS statement on six-minute walk test. Am J Respir Crit Care Med 167:1287","journal-title":"Am J Respir Crit Care Med"},{"key":"2000_CR9","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.clinph.2011.04.016","volume":"122","author":"LD Hobson-Webb","year":"2011","unstructured":"Hobson-Webb LD, Dearmey S, Kishnani PS (2011) The clinical and electrodiagnostic characteristics of Pompe disease with post-enzyme replacement therapy findings. Clin Neurophysiol 122:2312\u20132317","journal-title":"Clin Neurophysiol"},{"key":"2000_CR10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/mus.22296","volume":"45","author":"LD Hobson-Webb","year":"2012","unstructured":"Hobson-Webb LD, Kishnani PS (2012) How common is misdiagnosis in late-onset Pompe disease? Muscle Nerve 45:301\u2013302","journal-title":"Muscle Nerve"},{"key":"2000_CR11","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","volume":"161","author":"PS Kishnani","year":"2013","unstructured":"Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J (2013) Timing of diagnosis of patents with Pompe disease: data from the Pompe registry. Am J Med Genet A 161:2431\u20132443","journal-title":"Am J Med Genet A"},{"key":"2000_CR12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/GIM.0b013e3182142966","volume":"13","author":"D Forsha","year":"2011","unstructured":"Forsha D, Li JS, Smith PB, van der Ploeg AT, Kishnani P, Pasquali SK (2011) Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Genet Med 13:625\u2013631","journal-title":"Genet Med"},{"key":"2000_CR13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2796.2008.01966.x","volume":"264","author":"OI Soliman","year":"2008","unstructured":"Soliman OI, van der Beek NA, van Doorn PA, Vietter WB, Nemes A, Van Dalen BM et al (2008) Cardiac involvement in adults with Pompe disease. J Intern Med 264:333\u2013339","journal-title":"J Intern Med"},{"key":"2000_CR14","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ymgme.2011.08.011","volume":"104","author":"M Roberts","year":"2011","unstructured":"Roberts M, Kishnani PS, van der Ploeg AT, Muller-Felber W, Merlini L, Prasad S et al (2011) The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe Registry. Mol Genet Metab 104:574\u2013582","journal-title":"Mol Genet Metab"},{"key":"2000_CR15","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT Ploeg Van der","year":"2010","unstructured":"Van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med 362:1396\u20131406","journal-title":"N Engl J Med"},{"key":"2000_CR16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT Ploeg van der","year":"2012","unstructured":"van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ et al (2012) Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab 107:456\u2013461","journal-title":"Mol Genet Metab"},{"key":"2000_CR17","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","volume":"64","author":"ML Hagemans","year":"2005","unstructured":"Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT (2005) Disease severity in children and adults with Pompe disease related to age and duration. Neurology 64:2139\u20132141","journal-title":"Neurology"},{"key":"2000_CR18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.nmd.2008.04.010","volume":"18","author":"MC Malicdan","year":"2008","unstructured":"Malicdan MC, Noguchi S, Nonaka I, Saftig P, Nishino I (2008) Lysosomal myopathies: an excessive build-up in autophagosomes is too much to handle. Neuromuscul Disord 18:521\u2013529","journal-title":"Neuromuscul Disord"},{"key":"2000_CR19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10545-011-9393-6","volume":"35","author":"Y Furusawa","year":"2012","unstructured":"Furusawa Y, Mori-Yoshimura M, Yamamoto T, Sakamoto C, Wakita M, Kobayashi Y, Fukumoto Y et al (2012) Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: 2-year follow-up study. J Inherit Metab Dis 35:301\u2013310","journal-title":"J Inherit Metab Dis"},{"key":"2000_CR20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","volume":"14","author":"T Fukuda","year":"2006","unstructured":"Fukuda T, Ahearn M, Roberts A, Mattaliano RJ, Zaal K, Ralston E et al (2006) Autophagy and mistargeting of the therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther 14:831\u2013839","journal-title":"Mol Ther"},{"key":"2000_CR21","unstructured":"Myozyme Prescribing information. Genzyme Corporation. http:\/\/www.Myozyme.com"},{"key":"2000_CR22","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL (2011) The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 13:729\u2013736","journal-title":"Genet Med"},{"key":"2000_CR23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ajmg.c.31316","volume":"160","author":"E Lacana","year":"2012","unstructured":"Lacana E, Yao LP, Pariser AR, Rosenberg AS (2012) The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Am J Med Genet C Semin Med Genet 160:30\u201339","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2000_CR24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","volume":"106","author":"TT Patel","year":"2012","unstructured":"Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, Kishnani PS (2012) The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab 106:301\u2013309","journal-title":"Mol Genet Metab"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-014-2000-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-014-2000-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-014-2000-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:55:49Z","timestamp":1717548949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-014-2000-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,12]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2000"],"URL":"https:\/\/doi.org\/10.1007\/s10072-014-2000-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,12]]}}}